{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T08:05:18Z","timestamp":1763453118438,"version":"3.45.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"DOI":"10.7759\/cureus.97131","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T08:02:02Z","timestamp":1763452922000},"source":"Crossref","is-referenced-by-count":0,"title":["Fibrolamellar Hepatocellular Carcinoma: A Case Report of 25-Year Postoperative Survival"],"prefix":"10.7759","author":[{"given":"Kaito","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moriyuki","family":"Kiyoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iijima","family":"Tatsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuyo","family":"Yoshimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kyoden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","author":"Sangro B","year":"2025","unstructured":"Sangro B, Argemi J, Ronot M, et al.. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025, 82:315-74. 10.1016\/j.jhep.2024.08.028","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet JM","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al.. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021, 7:6. 10.1038\/s41572-020-00240-3","journal-title":"Nat Rev Dis Primers"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20096","article-title":"Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study","volume":"39","author":"El-Serag HB","year":"2004","unstructured":"El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004, 39:798-803. 10.1002\/hep.20096","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2023.102162","article-title":"Fibrolamellar hepatocellular carcinoma: an epidemiologic and 5-year cancer survival assessment based off SEER data","volume":"47","author":"Aloysius MM","year":"2023","unstructured":"Aloysius MM, Iskander P, Ahmed K, et al.. Fibrolamellar hepatocellular carcinoma: an epidemiologic and 5-year cancer survival assessment based off SEER data. Clin Res Hepatol Gastroenterol. 2023, 47:102162. 10.1016\/j.clinre.2023.102162","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2012.08.001","article-title":"A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma","volume":"215","author":"Mavros MN","year":"2012","unstructured":"Mavros MN, Mayo SC, Hyder O, Pawlik TM. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg. 2012, 215:820-30. 10.1016\/j.jamcollsurg.2012.08.001","journal-title":"J Am Coll Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1126\/science.1249484","article-title":"Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma","volume":"343","author":"Honeyman JN","year":"2014","unstructured":"Honeyman JN, Simon EP, Robine N, et al.. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014, 343:1010-4. 10.1126\/science.1249484","journal-title":"Science"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.285.6345.840","article-title":"High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma","volume":"285","author":"Paradinas FJ","year":"1982","unstructured":"Paradinas FJ, Melia WM, Wilkinson ML, Portmann B, Johnson PJ, Murray-Lyon IM, Williams R. High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J (Clin Res Ed). 1982, 285:840-2. 10.1136\/bmj.285.6345.840","journal-title":"Br Med J (Clin Res Ed)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.12.028","article-title":"Unique genomic profile of fibrolamellar hepatocellular carcinoma","volume":"148","author":"Cornella H","year":"2015","unstructured":"Cornella H, Alsinet C, Sayols S, et al.. Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology. 2015, 148:806-18.e10. 10.1053\/j.gastro.2014.12.028","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2015.11.052","article-title":"Protein kinase A catalytic subunit isoform PRKACA; History, function and physiology","volume":"577","author":"Turnham RE","year":"2016","unstructured":"Turnham RE, Scott JD. Protein kinase A catalytic subunit isoform PRKACA; History, function and physiology. Gene. 2016, 577:101-8. 10.1016\/j.gene.2015.11.052","journal-title":"Gene"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2008.12.009","article-title":"Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy","volume":"35","author":"Maniaci V","year":"2009","unstructured":"Maniaci V, Davidson BR, Rolles K, Dhillon AP, Hackshaw A, Begent RH, Meyer T. Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy. Eur J Surg Oncol. 2009, 35:617-21. 10.1016\/j.ejso.2008.12.009","journal-title":"Eur J Surg Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/XCS.0000000000000476","article-title":"Fibrolamellar hepatocellular carcinoma: comprehensive review of diagnosis, imaging, and management","volume":"236","author":"Aziz H","year":"2023","unstructured":"Aziz H, Brown ZJ, Panid Madani S, Kamel IR, Pawlik TM. Fibrolamellar hepatocellular carcinoma: comprehensive review of diagnosis, imaging, and management. J Am Coll Surg. 2023, 236:399-410. 10.1097\/XCS.0000000000000476","journal-title":"J Am Coll Surg"},{"key":"ref13","article-title":"Aggressive surgical management of recurrent lymph node and pancreatic head metastases of resected fibrolamellar hepatocellular carcinoma: a case report","volume":"13","author":"Wojcicki M","year":"2012","unstructured":"Wojcicki M, Lubikowski J, Post M, Chmurowicz T, Wiechowska-Kozlowska A, Krawczyk M. Aggressive surgical management of recurrent lymph node and pancreatic head metastases of resected fibrolamellar hepatocellular carcinoma: a case report. JOP. 2012, 13:529-32.","journal-title":"JOP"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-009-4035-4","article-title":"Mediastinal metastasis from a fibrolamellar hepatocellular carcinoma: report of a case","volume":"40","author":"Ichiki Y","year":"2010","unstructured":"Ichiki Y, Sugio K, Baba T, et al.. Mediastinal metastasis from a fibrolamellar hepatocellular carcinoma: report of a case. Surg Today. 2010, 40:360-4. 10.1007\/s00595-009-4035-4","journal-title":"Surg Today"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s1091-255x(97)80055-8","article-title":"Aggressive surgical management of fibrolamellar hepatocellular carcinoma","volume":"1","author":"Hemming AW","year":"1997","unstructured":"Hemming AW, Langer B, Sheiner P, Greig PD, Taylor BR. Aggressive surgical management of fibrolamellar hepatocellular carcinoma. J Gastrointest Surg. 1997, 1:342-6. 10.1016\/s1091-255x(97)80055-8","journal-title":"J Gastrointest Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S428741","article-title":"Treatment outcomes in patients with advanced fibrolamellar hepatocellular carcinoma under systemic treatment: analysis of clinical characteristics, management, and radiomics","volume":"10","author":"Da Fonseca LG","year":"2023","unstructured":"Da Fonseca LG, Yamamoto VJ, Trinconi Cunha M, et al.. Treatment outcomes in patients with advanced fibrolamellar hepatocellular carcinoma under systemic treatment: analysis of clinical characteristics, management, and radiomics. J Hepatocell Carcinoma. 2023, 10:1923-33. 10.2147\/JHC.S428741","journal-title":"J Hepatocell Carcinoma"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00147-4","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice","volume":"8","author":"Pinter M","year":"2023","unstructured":"Pinter M, Scheiner B, Pinato DJ. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice. Lancet Gastroenterol Hepatol. 2023, 8:760-70. 10.1016\/S2468-1253(23)00147-4","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-023-05621-z","article-title":"Treatment and prognosis of fibrolamellar hepatocellular carcinoma: a systematic review of the recent literature and meta-analysis","volume":"27","author":"Glavas D","year":"2023","unstructured":"Glavas D, Bao QR, Scarpa M, Ruffolo C, Brown ZJ, Pawlik TM, Spolverato G. Treatment and prognosis of fibrolamellar hepatocellular carcinoma: a systematic review of the recent literature and meta-analysis. J Gastrointest Surg. 2023, 27:705-15. 10.1007\/s11605-023-05621-z","journal-title":"J Gastrointest Surg"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1396420","article-title":"Advances in fibrolamellar hepatocellular carcinoma: a review","volume":"24","author":"Lim II","year":"2014","unstructured":"Lim II, Farber BA, LaQuaglia MP. Advances in fibrolamellar hepatocellular carcinoma: a review. Eur J Pediatr Surg. 2014, 24:461-6. 10.1055\/s-0034-1396420","journal-title":"Eur J Pediatr Surg"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260412","article-title":"Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation","volume":"26","author":"Pinna AD","year":"1997","unstructured":"Pinna AD, Iwatsuki S, Lee RG, et al.. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology. 1997, 26:877-83. 10.1002\/hep.510260412","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s005950200015","article-title":"Fibrolamellar hepatocellular carcinoma in a Japanese man: report of a case","volume":"32","author":"Yoshimi F","year":"2002","unstructured":"Yoshimi F, Asato Y, Amemiya R, Itabashi M, Nakamura K. Fibrolamellar hepatocellular carcinoma in a Japanese man: report of a case. Surg Today. 2002, 32:174-9. 10.1007\/s005950200015","journal-title":"Surg Today"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21703","article-title":"Outcome of patients with fibrolamellar hepatocellular carcinoma","volume":"106","author":"Stipa F","year":"2006","unstructured":"Stipa F, Yoon SS, Liau KH, et al.. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006, 106:1331-8. 10.1002\/cncr.21703","journal-title":"Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23658","article-title":"Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma","volume":"110","author":"Groeschl RT","year":"2014","unstructured":"Groeschl RT, Miura JT, Wong RK, et al.. Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma. J Surg Oncol. 2014, 110:412-5. 10.1002\/jso.23658","journal-title":"J Surg Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/98.2.175","article-title":"Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases","volume":"98","author":"Loy TS","year":"1992","unstructured":"Loy TS, Quesenberry JT, Sharp SC. Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases. Am J Clin Pathol. 1992, 98:175-9. 10.1093\/ajcp\/98.2.175","journal-title":"Am J Clin Pathol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S236475","article-title":"Prognostic significance of elevated preoperative serum CA125 levels after curative hepatectomy for hepatocellular carcinoma","volume":"13","author":"Huang Y","year":"2020","unstructured":"Huang Y, Zeng J, Liu T, et al.. Prognostic significance of elevated preoperative serum CA125 levels after curative hepatectomy for hepatocellular carcinoma. Onco Targets Ther. 2020, 13:4559-67. 10.2147\/OTT.S236475","journal-title":"Onco Targets Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-99-24229","article-title":"Hepatic uptake and biliary excretion of indocyanine green in the dog","volume":"99","author":"Wheeler HO","year":"1958","unstructured":"Wheeler HO, Cranston WI, Meltzer JI. Hepatic uptake and biliary excretion of indocyanine green in the dog. Proc Soc Exp Biol Med. 1958, 99:11-4. 10.3181\/00379727-99-24229","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2018.08.08","article-title":"Management of fibrolamellar hepatocellular carcinoma","volume":"7","author":"Chaudhari VA","year":"2018","unstructured":"Chaudhari VA, Khobragade K, Bhandare M, Shrikhande SV. Management of fibrolamellar hepatocellular carcinoma. Chin Clin Oncol. 2018, 7:51. 10.21037\/cco.2018.08.08","journal-title":"Chin Clin Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.286.6358.57","article-title":"High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma","volume":"286","author":"Sheppard KJ","year":"1983","unstructured":"Sheppard KJ, Bradbury DA, Davies JM, Ryrie DR. High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J (Clin Res Ed). 1983, 286:57. 10.1136\/bmj.286.6358.57","journal-title":"Br Med J (Clin Res Ed)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2530","article-title":"MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53","volume":"23","author":"Lakshmanan I","year":"2017","unstructured":"Lakshmanan I, Salfity S, Seshacharyulu P, et al.. MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53. Clin Cancer Res. 2017, 23:3906-17. 10.1158\/1078-0432.CCR-16-2530","journal-title":"Clin Cancer Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1621710","article-title":"Fibrolamellar carcinoma: recent advances and unresolved questions on the molecular mechanisms","volume":"38","author":"Lalazar G","year":"2018","unstructured":"Lalazar G, Simon SM. Fibrolamellar carcinoma: recent advances and unresolved questions on the molecular mechanisms. Semin Liver Dis. 2018, 38:51-9. 10.1055\/s-0037-1621710","journal-title":"Semin Liver Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.4952","article-title":"Enhanced recovery after surgery: a review","volume":"152","author":"Ljungqvist O","year":"2017","unstructured":"Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. JAMA Surg. 2017, 152:292-8. 10.1001\/jamasurg.2016.4952","journal-title":"JAMA Surg"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-009-9159-x","article-title":"An integrated multidisciplinary approach to implementation of a fast-track program for laparoscopic colorectal surgery","volume":"56","author":"Carli F","year":"2009","unstructured":"Carli F, Charlebois P, Baldini G, Cachero O, Stein B. An integrated multidisciplinary approach to implementation of a fast-track program for laparoscopic colorectal surgery. Can J Anaesth. 2009, 56:837-42. 10.1007\/s12630-009-9159-x","journal-title":"Can J Anaesth"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/435676-fibrolamellar-hepatocellular-carcinoma-a-case-report-of-25-year-postoperative-survival","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T08:02:03Z","timestamp":1763452923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/435676-fibrolamellar-hepatocellular-carcinoma-a-case-report-of-25-year-postoperative-survival"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.97131","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}